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Abstract
The purpose of this work was to carry out preclinical toxicity and bio-distribution studies
required for regulatory approval of a clinical trial application for Phase I clinical studies of
ONCOS-102 (Ad5/3-D24-GM-CSF) for therapy of advanced cancers (NCT01598129). The
study design, route of administration and dosage differs from the clinical protocol and in
more detail, investigate bio-distribution and toxicological profile of ONCOS-102 treatment in
animal model. The study was carried out in 300 hamsters divided into nine test groups–
three bio-distribution groups and six groups for analysis of toxicity. Hamsters received
ONCOS-102 by intracardial, intraperitoneal or subcutaneous injections. Additionally, one
group was administered twice a week with intraperitoneal injections of Cyclophosphamide.
The control animals were administered with NaCl solution without ONCOS-102 in the same
volume and the same way. No adverse effects of repeated administration of ONCOS-102
including body weight, food consumption, hematology and clinical chemistry parameters,
histopathology and bio-accumulation were observed in the course of 6-month administration
and following 3- month recovery period. All obtained findings indicate the treatment clinically
safe.
Introduction
Advanced, metastatic tumors often exhibit resistance to standard therapies, and thus novel,
safer and more effective treatment modalities are in high need [1, 2].
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Oncolytic adenoviruses are promising agents in cancer therapy. Their efficacy and safety
has been proven in several clinical studies [3–5].
ONCOS-102 is a serotype 5 human adenovirus with a chimeric 5/3 capsid for enhanced can-
cer cell transduction due to alternative receptor usage, and a 24 bp deletion in the Rb binding
site of the E1A gene, rendering the viral replication to target cells [3]. Importantly, ONCOS-102
codes for human granulocyte macrophage colony-stimulating factor (GM-CSF), a potent
immunostimulatory cytokine for enhanced anti-tumor immunity by recruiting and activating
APC (antigen presenting cells) [6, 7].
ONCOS-102 induces systemic anti-tumor T cell response in cancer patients by directly lys-
ing cancer cells and concomitantly causing a modulation of tumor microenvironment from
Th2- to Th1-type [8]. Next ONCOS-102 sensitizes tumor cells to other immunotherapies by
inducing a T-cell positive phenotype to an initially T-cell negative tumor mass [8]. Importantly
presented double mode of action of ONCOS-102 is an important factor needed to overcome
the major obstacle with regards to cancer immunotherapy—suppressive tumor microenviron-
ment [1].
The aim of the study was to evaluate the toxicological profile and bio-distribution of
ONCOS-102 after intracardial and repeated intraperitoneal or subcutaneous administration in
Syrian hamsters. The study was carried out in order to support clinical trial application of
ONCOS-102 (NCT01598129) for therapy of advanced cancers. The study was successfully




This pre-clinical study was performed in compliance with the Organization for Economic Co-
operation and Development (OECD), Principles of Good Laboratory Practice (GLP) C (97)
186/Final, Directive 2004/10/EC, The Czech law No. 378/2007 and Decree of Ministry of
Health and Ministry of Agriculture of the Czech Republic No. 86/2008 of Collection of laws
about Good Laboratory Practice for testing of drugs.
Animal welfare act compliance, ethics statement
The study was prepared for this type of experiment and approved by the Institutional Animal
Care and Use Committee (IACUC) and the Committee for Animal Protection of the Ministry
of Industry and Trade of the Czech Republic (10/2009). Animal care was in compliance with
the SOPs of BioTest s.r.o., the European convention for the protection of vertebrate animals
used for experimental and other scientific purposes (ETSV123), the Czech collection of laws
No. 246/1992, inclusive of the amendments, on the Protection of animals against cruelty, and
Public Notice of the Ministry of Agriculture of the Czech Republic, Collection of laws No. 207/
2004 as amended, on keeping and exploitation of experimental animals. BioTest s.r.o., is a
holder of the accreditation Certificate for user’s issued by Central Committee for Animal Pro-
tection of the Czech republic.
Procedures used in this report are designed to conform to accepted practices and to mini-
mize or avoid causing pain, distress, or discomfort to the animals. The number of animals
selected for use in this study was considered to be the minimum number necessary to meet sci-
entific and regulatory guidelines for this type of study. Twelve animals did not survive till their
scheduled necropsy. One animal (D3-TOX group) died during the acclimation period before
the start of the treatment. One animal from D2-BIO and three animals from D2-TOX died on
Day 1 during intracardial needle insertion, but before the virus injection. One animal from
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group C-TOX, one animal from D2-TOX, and one animal from D3-TOX died on Day 1
within several minutes after the intracardial virus administration. Four animals, which died
directly during administration, but before virus injection, were not necropsied, other three,
which died within several minutes after the administration, were necropsied. The cause of
death of all these animals was related to the unsuccessful intracardial application and was
not related to the treatment. One animal from D2-TOX was found dead on Day 27 (after 4
administrations) and one animal from D1-TOX died on Day 104. The cause of the death
was circulatory failure. One male from group D3-TOX was euthanized in the 18th week
of the study (Day 120) due to loss of incisors related to high age. One male from group
D3-TOX died in ether narcosis during final blood sampling (Day 255). All other animals
survived till their scheduled necropsy.
Test item–ONCOS-102
Adenovirus ONCOS-102 is a class II genetically modified micro-organism (GMM). The engi-
neering of ONCOS-102 has been described previously [3]. ONCOS-102 was produced by Bio-
vian (Turku, Finland) according to GLP and stored at -80˚C until use.
Test system–syrian hamsters
The study was carried out with 300 hamsters (Syrian hamsters, Mesocricetus auratus, males
and females, supplier by AnLab s.r.o, Czech Republic.) divided into nine test groups–three
groups for bio-distribution (C-BIO, D2-BIO and D2-BIO SC) and six groups for toxicity
analysis (C-TOX, D1-TOX, D2-TOX, D2-TOX SC, D2-TOX CP, D3-TOX). Animals were
sorted according to the body weight, and allocated to the dose group. Hamsters were housed
individually in Macrolon 2000P cages (Tecniplast, Italy) in barrier laboratory conditions
(BSL-2). Room temperature was 20–24˚C and the relative humidity between 30–70%. Fluo-
rescent lighting provided illumination approximately 12 hours per day. Feed, water con-
tainers and bedding were changed and sanitized at least once weekly. Hamsters were
acclimated for 7 days.
Dose procedure
Each hamster in a dose group (except D2-TOX SC and D2-BIO SC) received the indicated
dose (Table 1) of ONCOS-102 in sterile saline solution by intracardial injection (in isoflur-
ane anaesthesy) on day 1 and intraperitoneal injections on days 4, 8, and 15. D2-TOX SC
and D2-BIO SC groups were administered in the same intervals subcutaneously only.
Additionally, group D2-TOX CP was administered twice a week with intraperitoneal injec-
tions of Cyclophosphamide (120M1253V, Sigma Aldrich, Germany) in dose of 20 mg/kg
(diluted in saline). Control animals were administered with saline solution without
ONCOS-102 in the same volume and the same way. Administration followed in the same
manner on days 29, 57, 85, 113, 141 and 169. The first day of dosing is designated as day 1
of the study.
The study design, dosage and route of administration in the study was consulted and agreed
with regulatory authorities: European Medicines Agency (EMA) and Food and Drug Adminis-
tration (FDA). Medium (4.5 x 1010 VP/kg), high (4.5 x 1011 VP/kg), and very high (4.5 x 1012
VP/kg) doses of ONCOS-102 (i.e. 10x to 1000x the intended clinical dose w/w) were given
with CPO (20 mg/kg i.p.) on Day 1 (by intracardial [i.c.] injection), and Days 4, 8 and 15 (by i.
p. injection).
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Clinical observations
Daily observations. All hamsters were observed daily for clinical signs, morbidity or mor-
tality during acclimation and administration period and additionally 1 hour after each
ONCOS-102 administration. Onset, duration and severity of any signs were recorded.
Body weight and food consumption. All hamsters were individually weighed at delivery,
before the first administration, then weekly during the administration and recovery period
and before the necropsy. Individual food consumption was recorded weekly during acclima-
tion, administration and recovery periods in all TOX groups only.
Sampling and analysis
Blood analyses. Blood samples for hematology (S1 Table) and clinical chemistry (S2
Table), and for neutralizing antibodies, were collected from all TOX animals before adminis-
tration (day 7), at days 29, 190 and 255, and at days 29, 190 and 255, respectively. The animals
were fasted for approximately 12–18 hours before blood sampling, but water was provided ad
libitum. Blood samples were drawn under ether anesthesia from the retro-orbital venous.
DNA isolation and qPCR. The number of copies of adenoviral sequence (E1 region) and
hamster Gapdh sequence were determined in DNA samples. Samples of feces were isolated
using NucleoSpin kit, samples of urine and buccal swabs were isolated using NucleoSpin
Blood DNA isolation and serum samples were isolated using NucleoSpin Blood DNA isolation
kit according to the manufacturer´s instructions (Macherey-Nagel, Germany). In tissue sam-
ples the concentration of adenoviral sequence (primer FWE1: 5´-TCCGGT TTC TAT GCC
AAA CCT-3´, primer RVE1: 5´- TCC TCC GGT GAT AAT GAC AAG A-3´, probe adenoE1:
5- ATC GAT CCA CCC AGT GAC GAC-3) was normalized by the concentration of hamster’s
Gapdh sequence (primer FWGapdh: 5´- CAC CGA GGA CCA GGT TGTC T-3´, primer
RVGapdh: 5´-CATACC AGG AGA TGA GCT TTA CGA-3´, probe Gapdh: 5-CAA TGC CAG
CCC CAG CATC A-3) or by the total amount of DNA. Tissues and other samples (brain, heart,
optic nerves, liver, lungs, spleen, kidney, gonads, bone marrow, buccal swab, urine, feces) for
analysis of bio-distribution were collected on day 3 in groups C-BIO and D2-BIO and on day
29 in all BIO groups and on day 183 in groups C-BIO and D2- BIO.
Table 1. Treatment groups for toxicological and bio-distribution studies–allocation and dosing.
Group Designation Dose No. of animals
males females
C-BIO(Control) 0 (i.c./i.p.) 15 15
D2-BIO (Middle Dose) 4.5 x 1010 v.p./kg (i.c./i.p.) 15 15
D2-BIO SC (Middle Dose) 4.5 x 1010 v.p./kg (s.c.) 5 5
C-TOX (Control) 0 (i.c./i.p.) 25 25
D1-TOX (Low Dose) 4.5 x 109 v.p./kg (i.c./i.p.) 20 20
D2-TOX (Middle Dose) 4.5 x 1010 v.p./kg (i.c./i.p.) 20 20
D2-TOX CP (Middle Dose) 4.5 x 1010 v.p./kg (i.c./i.p.); 20mg/kg (i.p.) 20 20
D2-TOX SC (Middle Dose) 4.5 x 1010 v.p./kg (s.c.) 5 5
D3-TOX (High Dose) 4.5 x 1011 v.p./kg (i.c./i.p.) 25 25
BIO–bio-distribution groups, TOX–toxicity groups
ONCOS-102—Test item, Cyclophosphamide/CP–additive item
v.p./kg—virus particles per kg
(i.c./i.p.)–intracardial/intraperitoneal administration, (s.c./SC)–subcutaneous administration
https://doi.org/10.1371/journal.pone.0182715.t001
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Analysis of ONCOS-102-specific neutralizing antibodies. Serum was snap-frozen upon
collection and stored below -70˚C until transportation to analysis. Neutralizing antibody mea-
surements were done as previously described [9].
Necropsy
Necropsy was performed in TOX groups on day 29, 190 and 256. All animals were weighed
and examined externally. Any abnormalities were recorded with details of location, color,
shape and size. Samples of all tissues for analysis of neutralizing antibodies were taken in paral-
lel with samples collected for histology.
Whole organs or samples of the collected tissues were preserved in 4% neutral buffered
formaldehyde (S3 Table). The eyes, optic nerves, testes and epididymides were fixed in David-
son’s fluid and then moved to 4% neutral buffered formaldehyde.
Histopathology was performed for organs and tissues listed in S3 Table. Histopathological
examination was performed in all TOX animals except for D2-TOX SC (middle dose) group.
Tissues from all animals were paraffin embedded, cut at a nominal thickness of approximately
5μm, stained with haematoxylin and eosin (HE) and examined microscopically.
Data compilation and statistical analysis
Group mean, medians and standard deviations were calculated for body weights, food con-
sumption, hematology, clinical chemistry and DNA isolation using Graph Pad Prism software,
v4 (GraphPad Software, San Diego, CA). In addition, values were subjected to analysis of vari-




Twelve animals did not survive till their scheduled necropsy. The cause of death of all these
animals was related to the unsuccessful intracardial application and was not related to the
treatment agent. All tested animals were in good health status, and no severe signs of toxicity
were observed in-group. Blindness of right eye was observed in one male from the D2-TOX
group, probably as a consequence of blood sampling from retro-orbital plexus without relation
to the treatment. Tumescent testes were repeatedly observed in three animals from the same
group and in one male from group D1-TOX. All the other animals showed no clinical signs of
toxicity observed as: changes in activity, response to handling or other recorded signs.
Body weight. The mean body weight of all hamster groups decreased after the first admin-
istration when compared to the baseline, probably due to excessive handling (Figs 1 and 2).
The average body weight in the course of the acclimation was expressed as baseline. In the first
6 weeks of administration period mean body weight of males in all treated groups slightly
decreased, but subsequently returned to normal values. In the course of administration and
recovery periods, the mean body weight was virtually constant or slightly varied in both sexes
of all groups, which was in accordance with the age of the animals. No statistically significant
decrease in the mean body weight was observed in any test group when compared to the con-
trol. No influence of ONCOS-102 on body weight was observed.
Food consumption. The hamsters’ food consumption was recorded weekly during the
acclimation and administration periods (Fig 3). The average food consumption in the course
of the acclimation was expressed as baseline. The mean food consumption slightly decreased
after the first administration in most groups. Thereafter, a high variability in food
Toxicological and bio-distribution profile of oncolytic adenovirus ONCOS-102
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consumption was observed in all groups. Although there were many statistically significant dif-
ferences between groups in many study weeks, due to high variability no clear trends indicat-
ing treatment related changes in food consumption were found. No influence of ONCOS-102
on the hamsters’ food consumption in the course of the study administration period was
observed.
Hematology and clinical chemistry. Blood samples for hematology and clinical chemis-
try examinations were collected from all the animals on day 7 (Examination 1, before the first
ONCOS-102 administration), on day 29 (Examination 2), on day 190 (Examination 3, end of
the administration period) and on day 255 (S4 and S5 Tables).
Hematology: there were no changes in hematology parameters after the ONCOS-102
administration, except for the significantly higher values of MCV, MCH and MCHC in group
D2-TOX CP as compared to control in Examination 3, most probably caused by additive item
(Cyclophosphamide).
Clinical chemistry: no significant changes were observed in the mean serum activity of the
liver enzymes such as Lactate dehydrogenase (LDH), Alanine aminotransferase (ALT) and
Fig 1. Body weight (g)–BIO groups. (A)–males. (B)–females.
https://doi.org/10.1371/journal.pone.0182715.g001
Fig 2. Body weight (g)–TOX groups. (A)–males. (B)–females.
https://doi.org/10.1371/journal.pone.0182715.g002
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Aspartate aminotransferase (AST), except for the statistically significant higher activity of
LDH in the D3-TOX recovery males as compared to control recovery animals (Examination 4,
p<0.001). A slight decrease (up to 10% and within reference limits) in the mean total protein
(TP) values was recorded in dosed females (with statistically significance in the D1-TOX
(p<0.05), D2-TOX CP (p<0.05) and D3-TOX females (p<0.01)) on day 190 (Examination 3)
as compared to control. This finding corresponded with the statistically significant decrease in
the mean globulin values (Glo) in the D1-TOX (p<0.05) and D2-TOX CP (p<0.01) females.
No statistically significant differences were found in dosed males on Day 190.
No considerable changes were observed in the mean liver enzymes serum activity during
the study. No dose-related changes of the serum proteins were observed in dosed males.
Although the decrease in the serum proteins was recorded in dosed females on Day 190, all
the mean values varied within the reference limits and could be evaluated as biologically
insignificant.
Neutralizing antibodies in hamster’s sera. All virus-treated animals developed NAbs
against the virus (S1–S3 Figs). Dosing had an effect on the Nab formation, since the NAb
blocking effect in animals from group D1-TOX was statistically smaller (p<0.05 –p<0.001) in
comparison to the groups receiving 10-fold or 100-fold larger dose of virus (D2-TOX and
D3-TOX), respectively (S2 Fig). The latter groups had no statistically significant difference
when compared against each other. This possibly indicates some level of NAb saturation,
where the amount of NAbs increases in relation to the dose used up to a certain point, but
after reaching a certain limit the level of NAbs does no longer rise following the same kinetics
even if more virus is dosed. Overall, as expected, when compared to the other virus-injected
groups, D3-TOX had the highest levels of NAbs, even though the statistically significant differ-
ence (p<0.01 –p<0.001) was only observed against D1-TOX receiving 100-fold less virus, but
not the group receiving 10-fold less virus (D2-TOX), (S2 Fig). NAb levels at different time
points were further studied with the highest virus treatment dose (D3-TOX) by including a
late time point of 255 days (S1 Fig). These results indicate that NAbs already reached high
expression levels and activity 29 days after virus treatment. However, increased levels of NAbs
were formed by day 190, and the levels remained high until end of the experiment at Day 255.
Both adding cyclophosphamide or changing the injection route to subcutaneous decreased
NAb formation when compared to animals treated with same adenoviral dose without CP and
with default virus injection route (D2-TOX), (S3 Fig). This indicates that combination therapy
with CP or changing the administration route of adenovirus may alter NAb formation.
Fig 3. Food consumption–TOX groups. (A)–males. (B)–females.
https://doi.org/10.1371/journal.pone.0182715.g003
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Pathology
Gross pathology findings are presented in S6 and S7 Tables.
Liver: focal areas of mononuclear cell infiltration in the liver parenchyma were noticed
both in some control and the treated animals, therefore without relation to the treatment. A
surprising feature was irregular distribution of this lesion in different liver lobes. The cause of
this lesion is unclear, but due to the presence of this lesion in five control animals its relation
to the ONCOS-102 could be excluded.
Kidneys: the findings in the kidneys concerned both control and administered hamsters
(cortical scars, focal tubular dilatation, focal tubular basophilia, medullar mineralization, hya-
line casts) were without relation to the treatment.
Lungs: histopathological examination found encapsulated hematoma with marginal resorp-
tion and frequently with focal calcification. This lesion was in relation to the intracardial injec-
tion and subsequent hemorrhage into the lungs or thoracic cavity. Similarly, the pleural
adhesions and pleural fibrosis found in a few animals are a consequence of traumatic injury
caused by previous intracardial injection.
Male and female genital tract: the testes of three D1-TOX, three D2-TOX, four D2-TOX
CP, and one D3-TOX males showed adhesions of different extent to parietal layer of tunica
vaginalis accompanied by red- brown or yellowish color in two D2-TOX CP males. Reduced
size of testes was recorded in seven administered males. Similar adhesions and yellowish color
were observed in epididymides of two males from group D2-TOX SC and one male of group
D1-TOX. In one D3-TOX male, the epididymidis was enlarged, and in one D1-TOX this
organ was reduced in size.
All findings in the female genital tract were in relation to the advanced age of females, with-
out relation to the ONCOS-102.
Miscellaneous findings: all findings in the heart, except for spontaneous lipomatous atrophy
in one case, together with the findings in the mediastinum, retroperitoneum, abdominal cavity
and mesentery were a consequence of previous intracardial or intraperitoneal injection. Their
relation to the substance tested is secondary.
ONCOS-102 in the doses used did not cause gross or histopathological changes in the liver
and kidneys of surviving animals indicative of a toxic effect.
Other lesions found in the treated animals were either of spontaneous character or they
were not in direct relation to the ONCOS-102 administration.
Bio-distribution study
There was observed overall decrease of concentration of viral DNA from day 3 to Day 29 and
to Day 183. The total portion of quantifiable samples together with samples below LOQ was
55,6%, 45,0% and 37,5% in day 3, day 29 and day 183 of D2-Bio group respectively (Figs 4 and
5). The concentration of viral DNA is plotted in S4 Fig.
The highest accumulation of viral particles was observed in heart, liver, lung, spleen, kidney
and bone marrow. The Kruskal-Wallis test and Dunn’s Multiple Comparison Test showed sig-
nificant changes (p<0.05) of viral DNA concentration in heart, liver, lung and spleen. Except-
ing spleen the significant changes were registered between day 3 and day 29 and between day 3
and 183. The significant change in spleen was registered only between Day 3 and Day183. In
bone marrow and kidney was not registered significant change. The concentration in these tis-
sues was lower than 10 copies per ng of DNA. The distribution of virus in animals from group
D2-Bio SC is very limited in comparison to the group D2-Bio. The content of viral DNA in
serum samples from day 29 was low. The number of positive samples and samples bellow LOQ
was 40%, 55% and 85% in D1-TOX, D2-TOX and D3-TOX group respectively (Fig 6). The
Toxicological and bio-distribution profile of oncolytic adenovirus ONCOS-102
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number of positive samples and samples bellow LOQ in D2-TOX CP and D2-TOX SC was
40%.
Discussion
Metastatic tumors exhibit resistance to standard therapies, therefore new and more effective
treatment modalities are in high need [1, 2].
Oncolytic adenoviruses have shown a potential for the treatment of cancer. They have been
tested extensively in hundreds of preclinical studies and clinical trials. Importantly the safety
of adenoviral cancer gene therapy has been very well studied and considered a safe therapeutic
system [10–12], but only 2 products [13, 14] have been approved thus far—mainly due to low
anti-cancer efficacy. Therefore new approaches are focused on improving the efficacy by com-
binatory treatment options with chemotherapy [15–17], immune checkpoint inhibitors [18,
19], and radiotherapy [13, 20].
The aim of this study was to evaluate the safety profile of the ONCOS-102 after administra-
tion in Syrian hamsters. Study was performed to support clinical trial application of ONCOS-
102 (NCT01598129) for therapy of advanced cancers.
ONCOS-102 is an oncolytic adenovirus, designed to act as anti-cancer agent, by exhibiting
dual mode of action: i) to selectively kill tumor cells and ii) to induce anti-tumor immune
responses. Its anticancer efficacy has been already shown in numerous pre-clinical studies on
melanoma, soft tissue sarcoma and safety has been assessed in Phase I study (NCT01598129)
[8, 21]. Administration of ONCOS-102 for advanced solid tumor patients resulted in promi-
nent infiltration of CD8+ lymphocytes, and induction of Th1-type polarization in the tumor
microenvironment [8, 21].
Human adenovirus serotype 5 is a species-specific virus. It does not replicate to the same
extent as in humans in most animal models. However, Syrian hamsters have been reported as
semi-permissive to human adenovirus [22]. Therefore, it is a suitable animal model for toxico-
logical and bio-distribution studies with replicating adenovirus. This is also the position taken
by the national authorities in the USA and Europe, thus hamster was selected as a relevant ani-
mal model for toxicity testing of ONCOS-102 in this study. The injection routes were selected
Fig 4. Portions of final results in days and treatment groups. ALQ–samples with detection of adenoviral
sequence above limit of quantification (positive samples), BLQ–below limit of quantification, BLD–below limit
of detection, N.D.–not detected.
https://doi.org/10.1371/journal.pone.0182715.g004
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for the following reasons: systemic administration is considered the most toxic, i.e. this route
of administration, if any, would be the most likely to lead to toxicity. However, in hamsters,
reliable i.v. injection is difficult and thus i.c. was used as the best-available form of systemic
delivery. However, this cannot be performed repeatedly and thus the treatment was continued
with i.p. injections. Since the animals had no tumours, i.t. administration was not an option
and i.p. injection was considered the next best choice to simulate the overall toxicity and bio-
distribution profile achievable with i.t. injection.
The treatment with ONCOS-102 did not cause any adverse effects on body weight and food
consumption. Additionally, studies showed no considerable differences in hematology and
clinical chemistry parameters in treated groups when compared to control animals after 26
weeks of the study.
Fig 5. Portions of final results in sample types from D2-Bio group in days 3, 29 and 183. ALQ–samples
with detection of adenoviral sequence above limit of quantification (positive samples), BLQ–below limit of
quantification, BLD–below limit of detection, N.D.–not detected.
https://doi.org/10.1371/journal.pone.0182715.g005
Toxicological and bio-distribution profile of oncolytic adenovirus ONCOS-102
PLOS ONE | https://doi.org/10.1371/journal.pone.0182715 August 10, 2017 10 / 15
Presented overall findings do not surprise, since extensive clinical and non-clinical evidence
demonstrate benign safety profile of adenovirus. Hundreds of cancer patients have been
treated with replicating competent serotype 5 adenovirus Onyx-015 (E1B attenuated) in
numerous clinical trials [23, 24]. Onyx-015 was generally well tolerated at doses of up to
2×1012 particles by intratumoral, intraperitoneal, hepatic arterial and intravenous administra-
tion. No dose limiting toxicities (DLTs) have been identified by any route of administration.
Flu-like symptoms (fever, rigors) were the most typical toxicities and were mostly seen in can-
cer patients treated intravascularly [24]. Similar observations with no DLTs have been reported
in a Phase 1 study of 18 melanoma patients receiving combination therapy with T-VEC and
anti-CTLA-4 antibody [25]. No dose-limiting toxicity or maximum tolerated dose (MTD) has
been noticed as well in Phase 1 clinical trial of intratumoral infusion of reovirus for the treat-
ment of recurrent malignant gliomas [26].
Indeed thousands of patients were treated in many trials testing HSV, adenovirus, Reolysin
and very importantly all studies were without any major virus-related complication, and the
assessment of DLT and MTD has been noticed in any trial [27].
We conclude that under the test conditions used, the repeated administration of hamsters
with ONCOS-102 was well tolerated, without significant signs indicating toxic effects.
Supporting information
S1 Table. Hematology parameters.
(DOC)
S2 Table. Clinical chemistry parameters.  Day 3 and 190  Day 255.
(DOCX)
S3 Table. Histopathology organ and tissue list.
(DOCX)
S4 Table. Gross pathology findings (day 29) summary.
- organ examined, no pathological findings
Fig 6. Portions of final results in samples of serum from TOX groups in day 29, 190 and 260. ALQ–
samples with detection of adenoviral sequence above limit of quantification (positive samples), BLQ–below
limit of quantification, BLD–below limit of detection, N.D.–not detected.
https://doi.org/10.1371/journal.pone.0182715.g006
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/ organ not examined
NA not applicable
GRADE 1 minimal/very few/very small
GRADE 2 slight/few/small
GRADE 3 moderate/moderate number/moderate size
GRADE 4 marked/many/large
) finding unilateral in paired organs
P finding present, severity not scored
(DOCX)
S5 Table. Gross pathology findings (day 190 and day 256) summary.
- organ examined, no pathological findings
/ organ not examined
NA not applicable
GRADE 1 minimal/very few/very small
GRADE 2 slight/few/small
GRADE 3 moderate/moderate number/moderate size
GRADE 4 marked/many/large
) finding unilateral in paired organs
P finding present, severity not scored
(DOCX)
S6 Table. Hematology analysis.
Statistically significant difference at the 95.0% confidence level is pointed up in bold
x Normality test not passed, which tends to invalidate the tests comparing the standard
deviations
 Statistically significant difference only between means test groups D1-TOX, D2-TOX,
D2-TOX CP, D2-TOX SC or D3-TOX versus control group C-TOX
 Statistically significant difference only between medians test groups D1-TOX, D2-TOX,
D2-TOX CP, D2-TOX SC or D3-TOX versus control group C-TOX
 Statistically significant difference between means and medians test groups D1-TOX,
D2-TOX, D2-TOX CP, D2-TOX SC or D3-TOX versus control group C-TOX
+ statistically significant difference among standard deviations (F test)
# no variablity in one of the columns
(DOCX)
S7 Table. Clinical chemistry analysis.
Statistically significant difference at the 95.0% confidence level is pointed up in bold
x Normality test not passed, which tends to invalidate the tests comparing the standard
deviations
 Statistically significant difference only between means test groups D1-TOX, D2-TOX,
D2-TOX CP, D2-TOX SC or D3-TOX versus control group C-TOX
 Statistically significant difference only between medians test groups D1-TOX, D2-TOX,
D2-TOX CP, D2- TOX SC or D3-TOX versus control group C-TOX
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 Statistically significant difference between means and medians test groups D1-TOX,
D2-TOX, D2-TOX CP, D2-TOX SC or D3-TOX versus control group C-TOX
+ statistically significant difference among standard deviations (F test)
# no variablity in one of the columns
(DOCX)
S1 Fig. NAb activity in serum at 29 and 190 days after starting the treatments. The lowest,
medium and highest dose of virus treatment escalated from 1 to 100-fold (D1-TOX 1x;
D2-TOX 10x and D3-TOX 100x). Bars present NAb blocking effect ± SEM. Statistical analyses
was performed with LSD post hoc comparisons test. Horizontal lines indicate statistically sig-
nificant differences between sampling days within a group. Stars indicate statistical signifi-
cance between treatment groups D1-TOX vs. D2-TOX/D3-TOX ( = P 0.001;  = P 0.01
and  = P 0.05). There was no statistically significant difference between D2-TOX and
D3-TOX groups either sampling days.
(TIFF)
S2 Fig. NAb activity in hamsters’ serum at 29, 190 and 255 days after the highest dose of
virus treatment (D3-TOX 100x). Bars present NAb blocking effect ± SEM. Statistical analyses
has been performed with LSD post hoc comparisons test.
(TIFF)
S3 Fig. NAb activity in hamsters serum after 29 days treatment with medium (10x) dose of
adenovirus either intracardially/intraperitoneally (D2-TOX), with cyclophosphamide added
(D2-TOX CP) or subcutaneously (D2-TOX SC). Bars present NAb blocking effect ± SEM. Sta-
tistical analyses has been performed with LSD post hoc comparisons test ( = P 0.001;  =
P 0.01 and  = P 0.05).
(TIFF)
S4 Fig. Medians of logarithms of ratio Ad5/ng DNA in tissues from Day 3, 29 and 183 of
D2-Bio group. Brain, Gonads, Optic nerves, Feces, Buccal swabs and Urine are not plotted.
The whiskers represent standard deviation.
(TIF)
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